Ceftazidime + Avibactam
Generic Details
Generic Name
Ceftazidime-Avibactam
Other Names
- Ceftazidime/Avibactam
- Avycaz
Drug Class
- Combination of a cephalosporin antibiotic and a beta-lactamase inhibitor
Chemical Formula
C22H30N12O8S2
Molecular Weight
716.677 g/mol
Mechanism of Action
- Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
- Avibactam inhibits beta-lactamases, enzymes that can inactivate beta-lactam antibiotics.
Indications
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired bacterial pneumonia
- Ventilator-associated bacterial pneumonia
Common Dosage Forms
- Powder for solution for injection or infusion
Typical Dosage
- 2.5 grams intravenously every 8 hours
Pediatric Dosage
- Dosage varies based on weight and age, consult a pediatrician
Geriatric Dosage
- Dosage adjustments may be necessary based on kidney function
Side Effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Rash
- Elevations in liver enzymes
Contraindications
- Hypersensitivity to cephalosporins or beta-lactamase inhibitors
Pregnancy Category
- Category B - Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Lactation Safety
- Use with caution; may pass into breast milk at low levels
Drug Interactions
- Probenecid may increase levels of ceftazidime
- Concomitant use with nephrotoxic drugs may increase risk of kidney damage
Overdose Symptoms
- Seizures
- Encephalopathy
Antidote for Overdose
- Supportive care and monitoring
Storage Conditions
- Store powder for solution at controlled room temperature (20°C to 25°C)
Pharmacokinetics
- Absorption: Ceftazidime: Not absorbed orally; Avibactam: Well absorbed after oral administration
- Distribution: Both drugs distribute well into body tissues
- Metabolism: Ceftazidime: Minor metabolism in the liver; Avibactam: Minimal metabolism
- Excretion: Primarily renal for both drugs
Precautions
- Renal impairment may require dosage adjustments
- Monitor for signs of anaphylaxis during administration
Warnings
- Risk of Clostridium difficile-associated diarrhea
- Increased mortality in patients with carbapenem-resistant bacteria